A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

Patients with asymptomatic (smoldering) multiple myeloma (AMM) have a high risk of transformation to active multiple myeloma (MM). Bisphosphonates such as zoledronic acid (ZLD) reduce skeletal events in MM and the immunomodulatory agent thalidomide (Thal) has proven effectiveness in active MM. We hy...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Witzig, TE, Laumann, KM, Lacy, MQ, Hayman, SR, Dispenzieri, A, Kumar, S, Reeder, CB, Roy, V, Lust, JA, Gertz, MA, Greipp, PR, Hassoun, H, Mandrekar, SJ, Rajkumar, SV
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3912579/
https://ncbi.nlm.nih.gov/pubmed/22902362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2012.236
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars